Clinical Evaluation of the GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV *PLUS* Combination Test

Grant Johnson[1,2], Branden S.J. Gregorchuk[3], Arek Zubrzycki[1], Kurt Kolsun[3,4], Adrienne F.A. Meyers[3,5], Paul A. Sandstrom[3,5], Michael G. Becker[3,4,*]

[1] Laboratory Medicine and Infection Prevention and Control, Lakeridge Health, Oshawa, Ontario, Canada.

[2] Ontario Tech University, Oshawa, Ontario, Canada.

[3] National HIV and Retrovirology Laboratories, National Microbiology Laboratory Branch, JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, Canada

[4] Department of Microbiology, University of Manitoba, Winnipeg, Canada

[5] Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada

* Correspondence: michael.glen.becker@phac-aspc.gc.ca

Abstract

The Cepheid® GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV *PLUS* combination test (*PLUS* Assay) received Health Canada approval in January 2022. The *PLUS* Assay is similar to the SARS-CoV-2/Flu/RSV combination test, with the exception of an additional SARS-CoV-2 target that was included to improve assay robustness against emerging variants. The performance characteristics of the SARS-CoV-2/Flu/RSV *PLUS* combination test were assessed at the Lakeridge Health Oshawa Hospital Centre and the National Microbiology Laboratory of Canada. The *PLUS* Assay was directly compared to the Xpert Xpress SARS-CoV-2/Flu/RSV combination test using SARS-CoV-2 culture from five variants and remnant clinical specimens collected across multiple waves of the COVID-19 pandemic. This included 110 clinical specimens positive for SARS-CoV-2, Influenza A, Influenza B, RSVA, and/or RSVB and an additional 11 mixed samples to screen for target interactions. Additionally, 50 samples negative for all pathogens were included in this comparison. The *PLUS* Assay showed a high percent agreement with the widely used SARS-CoV-2/Flu/RSV combination test. Based on the findings from this study, the *PLUS* Assay and the Xpert SARS-CoV-2/Flu/RSV combination test results are largely consistent as there was no observed difference in sensitivity, specificity, reported Ct value, or time to result when challenged with various SARS-CoV-2 variants.

Introduction

The coronavirus disease 2019 (COVID-19) pandemic has lead to an enormous demand for diagnostic testing. To this end, numerous antigen and molecular SARS-CoV-2 rapid tests have been approved by the United States Food and Drug Administration and Health Canada, including the Cepheid GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV Combination Test. The GeneXpert and its associated COVID-19 cartridges perform a rapid, fully-automated, and self-contained multiplex RT-qPCR tests with run times of 45 minutes or less (Cepheid Package Insert, 2021). The Xpert SARS-CoV-2/Flu/RSV assay targets two SARS-CoV-2 genomic regions, the envelope (E) and the nucleocapsid (N2) returning a cycle threshold (Ct) value if the target is detected as well as its qualitative result interpretation within 45 amplification cycles. The results for the SARS-CoV-2/Flu/RSV combination test reports the fluorescence values for both the E and N2 targets of SARS-CoV-2 as a single result as they occupy the same fluorescence channel. Additionally, the Xpert SARS-CoV-2/Flu/RSV combination test is able to detect influenza A, influenza B as well as respiratory syncytial virus (RSV), and will report their respective Ct values.

As SARS-CoV-2 variants of concern continue to emerge worldwide, Cepheid developed a new formulation of their Xpert SARS-CoV-2/Flu/RSV combination test, the Xpert SARS-CoV-2/Flu/RSV *PLUS* combination test (referred to hereafter as the *PLUS* Combination Test). The *PLUS* Combination Test has an additional SARS-CoV-2 target, RNA-Dependent RNA Polymerase (RdRp), to help improve assay robustness against novel SARS-CoV-2 variants. RdRp (also known as nsp-12) is the catalytic subunit of multi-subunit polymerase complex which, along with nsp-7 and nsp-8, forms the minimal core components for SARS-CoV-2 RNA synthesis (Peng *et al.,* 2020). To date, there has been no identified RdRp modifications, with this region being considered relatively stable target due to its conserved function (te Velthuis *et al.,* 2009; Pachetti *et al.,* 2020; Peng *et al.,* 2020). RdRp is measured on the same fluorescence channel as targets E and N2, and thus a single Ct value is reported for SARS-CoV-2.

As a rapid near-point-of-care device, the GeneXpert system is currently used as a testing option to improve turnaround times in major health centres, and is used heavily in critical care

settings (Jokela *et al.*, 2020; Gotham *et al.*, 2021). Additionally, the GeneXpert has been a reliable

tool for decentralized testing in remote and isolated Canadian communities (Respiratory Virus

Infections Working Group, 2020) where access to large, well-equipped laboratories is not

possible (Berry *et al.*, 2020; Jokela *et al.*, 2020; Gotham *et al.*, 2021; Yau *et al.*, 2021; Rong *et al.*,

2022). It has also been used internationally by the World Health Organization in developing

countries during their response to the COVID-19 pandemic (Rakotosamimanana *et al.*, 2020;

World Health Organization, 2020).

The individual Xpert Xpress SARS-CoV-2 and Xpert Xpress Flu/RSV assays have

demonstrated high sensitivity in numerous analytical and clinical studies with company

reported sensitivity of 100% (n=35) at 250 copies (cp)/mL for its SARS-CoV-2 assay; independent

studies have reported a limit of detection (LOD) ranging from 8.3 – 60 cp/mL (3–4). Indeed, the

assay has shown excellent agreement with the Roche Cobas 6800 system (Broder *et al.*, 2020;

Goldenberger *et al.*, 2020; Lieberman *et al.*, 2020; Moran *et al.*, 2020; Smithgall *et al.*, 2020; Tham *et

al.*, 2021), the Hologic Panther Fusion (Hogan *et al.*, 2020), as well as laboratory-developed RT-

qPCR tests (Lieberman *et al.*, 2020; Wolters *et al.*, 2020). A recent systematic review of the Xpert

Xpress assay indicated an overall specificity and sensitivity of 97% based on a selection of 11

studies (Goldenberger *et al.*, 2020). As the GeneXpert is present a plethora of settings (including

clinics, hospitals, health centres, nursing stations), an independent evaluation of the recently

approved *PLUS* Combination Test ahead of the approaching flu season is essential.

In our study, remnant clinical samples of SARS-CoV-2, influenza A (H3 and H1 2009),

influenza B, RSVA, and RSVB were used to evaluate the *PLUS* Combination Test and compare

it to the SARS-CoV-2/Flu/RSV Combination Test. This evaluation was performed in two

independent laboratories, the National Microbiology Laboratory (NML; Winnipeg, Canada) and

Lakeridge Health Oshawa Hospital (Oshawa, Canada). The SARS-CoV-2 samples used in this

study were collected across multiple waves of the pandemic, and included SARS-CoV-2 Alpha,

Delta, Omicron BA.1, and Omicron BA.2 variants. Additionally, inactivated SARS-CoV-2

culture from five variants was tested on both assays. No difference was observed between the

assays concerning sensitivity, reported Ct value, run time, or specificity.

Materials and Methods

<u>Clinical Specimens</u>

Remnant universal transport media (UTM) from nasopharyngeal or nasal clinical swabs collected at the Cadham Provincial Laboratory (Winnipeg, Canada), Lakeridge Health Oshawa Hospital (Oshawa, Canada), and the Public Health Ontario Laboratory (Toronto, Canada) were used. Study samples included 50 clinical specimens negative for SARS-CoV-2, Influenza A, Influenza B, and RSV, with an additional 99 clinical positive specimens containing any one or more of the following pathogens: SARS-CoV-2, Influenza A, Influenza B, or RSV. Fifty-nine of the study samples (50 negatives, 7 COVID-19 positive, 2 Influenza positive) were obtained from prospective sampling of patients presenting with COVID-19 symptoms. The remainder of the study samples were previously characterized by laboratory-developed RT-qPCR tests (i.e. the ResPlex Assay or the Cepheid GeneXpert with the SARS-CoV-2/Flu/RSV Combination Test; Supplemental Data 1). Selected samples were stratified to cover a wide range of Ct values, from approximately 15-40. To simulate patient coinfection with multiple viruses, remnant transport media from an additional 26 clinical specimens was mixed in various combinations to create 11 contrived samples, each containing two or three different respiratory viral pathogens (Supplemental Data 1). All samples used in this study were research ethics board-exempt, anonymized, diagnostic samples used for assay validation. To determine overall test agreement, 300 µL of transport media from nasal or nasopharyngeal swabs was tested in parallel with the SARS-CoV-2/Flu/RSV combination test and the *PLUS* Combination Test. To mimic coinfection, clinical samples containing SARS-CoV-2, Influenza A, Influenza B, RSVA, or RSVB were combined in equal volumes to represent coinfection of two or three respiratory viruses, and tested using both Xpert assays.

<u>Gamma-irradiated SARS-CoV-2 culture</u>

High-titre inactivated SARS-CoV-2 culture of the Alpha (B.1.1.7), Delta (B.1.617.2),

Omicron BA.1 (BA.1), Omicron BA.2 (BA.2), and wild type (WA-1) variants was provided by

the Special Pathogens Program of the National Microbiology Laboratory Branch (NMLB;

Winnipeg, MB). SARS-CoV-2 variants were propagated in Vero cells in Minimal Essential

Medium and clarified by low speed centrifugation. The viral supernatant was inactivated via

gamma-irradiation using a Gammacell 220 Cobalt-60 irradiator with a total exposure of three

Mrad of radiation. The reported stock concentrations of the viral variant preparations were

2.1×10^6 PFU/mL (Alpha), 2.3×10^5 PFU/mL (Delta), 2.1×10^5 PFU/mL (Omicron BA1), 1.9×10^5

PFU/mL (Omicron BA.2), and 1.2×10^6 PFU/mL (wild type). Inactivated culture fluid was serially

diluted in UTM and Ct values were determined using the GeneXpert® Xpert® Xpress SARS-

CoV-2 assay. Dilutions were performed to obtain Ct values of approximately 33 and 36,

approaching the limit of detection of the GeneXpert assay. Ct values were converted into cp/mL

using a standard curve (Becker *et al.*, 2020). Characterization of dilutions are summarized in

Table 1. 300 µL of the diluted culture fluid was tested in duplicate using both the SARS-CoV-

2/Flu/RSV combination test and the *PLUS* Combination Test.

Results

Inactivated gamma-irradiated SARS-CoV-2 culture of five isolates (Wild-Type (WA-1),

Alpha (B.1.1.7), Delta (B.1.617.2), Omicron (BA.1), and Omicron (BA.2)) were used to investigate

the performance of the *PLUS* Combination Test against current or previous circulating variants.

A panel of five cultured SARS-CoV-2 isolates was tested with the SARS-CoV-2/Flu/RSV

combination test and the *PLUS* Combination Test (Table 1). All variants were detected with

both assays at all dilutions and replicates. Additionally, SARS-CoV-2 positive and SARS-CoV-2

negative clinical samples were tested with both the *PLUS* Combination Test and SARS-CoV-

2/Flu/RSV combination test (Table 2). The Ct values of SARS-CoV-2 positive samples ranged

from 15.6 to 43.5 (Fig. 1; Supplemental Data 1). There was 100% agreement between both assays,

with 57 positives and 103 negatives detected (Table 2). There was a high level of correlation

between the SARS-CoV-2 Ct values reported with both of the assays (Figure 1; $R^2 = 0.973$), with

an average standard deviation of 0.49 Ct values between the reported results (Supplemental
Data 1).

The above process was repeated for clinical samples containing Influenza A, Influenza B,
and RSV. Similarly, results were highly consistent between the *PLUS* Combination Test and
SARS-CoV-2/Influenza/RSV combination test, with overall percent agreements of 100%, 99.4%,
and 100% for influenza A, influenza B, and RSV, respectively (Table 3). Likewise, high
correlations were observed between the Ct values reported by both Xpert assays for influenza A
(Figure 1; R^2 = 0.978), influenza B (R^2 = 0.984), and RSV (R^2 = 0.975). Variance between the Ct
values reported by each assay was also low for all targets, with an average Ct value standard
deviation of 0.22 for influenza A, 0.24 for influenza B, and 0.36 for RSV (Supplemental Data 1).
The average run time from insertion of the cartridge to its ejection was timed for both the *PLUS*
Combination Test and SARS-CoV-2/Flu/RSV Combination Test. There was no difference in run
time between the two assays, with an average of 36.5 minutes to assay completion
(Supplemental Data 1).

Discussion and Conclusion

In an effort to improve assay performance against emerging SARS-CoV-2 variants the
PLUS Combination Test introduces an additional SARS-CoV-2 target (RdRp), as this region has
is unmodified in all circulating variants of concern (te Velthuis *et al.*, 2009; Pachetti *et al.*, 2020;
Peng *et al.*, 2020). Here, we investigated the performance characteristics of the *PLUS*
Combination Test comparing it to the SARS-CoV-2/Flu/RSV combination test authorized for use
in Canada since January, 2021. This study used a total of 160 clinical samples (including
mixtures) that were processed at two independent institutions, of which 110 samples were
positive for SARS-CoV-2, influenza A, influenza B, RSVA, and/or RSVB. There was no
observable difference in assay run time, sensitivity, specificity, or reported Ct value between the
PLUS Combination Test and SARS-CoV-2/Flu/RSV combination test. Overall, the results
between the two assays were nearly identical for all targets, with agreement approaching 100%
and a standard deviation of <0.5 Ct values. This observation was consistent for all variants
tested. These results demonstrate that the Ct value for RdRp detection of SARS CoV-2 likely

falls at or above the E and N2 targets producing little to no change to the reported Ct value. In

conclusion, as the performance characteristics of the tests are nearly identical, the *PLUS*

Combination Test can effectively replace the SARS-CoV-2/Flu/RSV combination test.

References

Becker, M. G. *et al.* (2020) 'Recommendations for sample pooling on the Cepheid GeneXpert® system using the
Cepheid Xpert® Xpress SARS-CoV-2 assay', *PLOS ONE*. Edited by J.-L. E. Darlix. Public Library of Science, 15(11), p.
e0241959. doi: 10.1371/journal.pone.0241959.

Berry, L. *et al.* (2020) 'Point of care testing of Influenza A/B and RSV in an adult respiratory assessment unit is
associated with improvement in isolation practices and reduction in hospital length of stay', *Journal of Medical*
Microbiology, 69(5), pp. 697–704. doi: 10.1099/jmm.0.001187.

Broder, K. *et al.* (2020) 'Test agreement between roche cobas 6800 and cepheid genexpert xpress sars-cov-2 assays
at high cycle threshold ranges', *Journal of Clinical Microbiology*, 58(8). doi: 10.1128/JCM.01187-20.

Cepheid Package Insert (2021) 'Xpert ® Xpress SARS-CoV-2/Flu/RSV Instructions For Use with GeneXpert Dx or
GeneXpert Infinity Systems'. Cepheid, 302–5707(Rev. A).

Goldenberger, D. *et al.* (2020) 'Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay', *Journal of*
Virological Methods, 284(July), pp. 8–10. doi: 10.1016/j.jviromet.2020.113925.

Gotham, D. *et al.* (2021) 'Public investments in the development of GeneXpert molecular diagnostic technology',
PLoS ONE, 16(8 August). doi: 10.1371/journal.pone.0256883.

Hogan, C. A. *et al.* (2020) 'Five-minute point-of-care testing for SARS-CoV-2: Not there yet', *Journal of Clinical*
Virology. Elsevier B.V., 128. doi: 10.1016/J.JCV.2020.104410.

Jokela, P. *et al.* (2020) 'SARS-CoV-2 sample-to-answer nucleic acid testing in a tertiary care emergency department:
evaluation and utility', *Journal of Clinical Virology*. Elsevier B.V., 131. doi: 10.1016/J.JCV.2020.104614.

Lieberman, J. *et al.* (2020) 'Comparison of Commercially Available and Laboratory Developed Assays for in vitro
Detection of SARS-CoV-2 in Clinical Laboratories', *medRxiv*. Cold Spring Harbor Laboratory Press, p.
2020.04.24.20074559. doi: 10.1101/2020.04.24.20074559.

Moran, A. *et al.* (2020) 'The Detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas
SARS-CoV-2 Assays', *Journal of Clinical Microbiology*. American Society for Microbiology Journals. doi:
10.1128/JCM.00772-20.

Pachetti, M. *et al.* (2020) 'Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA
polymerase variant', *J Transl Med*, 18, p. 179. doi: 10.1186/s12967-020-02344-6.

Peng, Q. *et al.* (2020) 'Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase
Complex from SARS-CoV-2', *Cell Reports*, 31(11). doi: 10.1016/j.celrep.2020.107774.

Rakotosamimanana, N. *et al.* (2020) 'GeneXpert for the diagnosis of COVID-19 in LMICs', *The Lancet Global Health*.
Elsevier Ltd, 8(12), pp. e1457–e1458. doi: 10.1016/S2214-109X(20)30428-9.

Respiratory Virus Infections Working Group (2020) 'Canadian Public Health Laboratory Network: Prioritized
support for northern, remote and isolated communities in Canada', *Can Commun Dis Rep*, 46(10), pp. 322–323.
doi: 10.14745/ccdr.v46i10a02.

Rong, K. *et al.* (2022) 'Validation of the Cepheid Xpert® Xpress SARS-CoV-2 using upper and lower respiratory tract
specimens', *European Journal of Microbiology and Immunology*. Akadémiai Kiadó, 12(1), pp. 18–21. doi:
10.1556/1886.2022.00003.

Smithgall, M. C. *et al.* (2020) 'Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid

Detection of SARS-CoV-2', *bioRxiv*. Cold Spring Harbor Laboratory, p. 2020.04.22.055327. doi:
10.1101/2020.04.22.055327.

Tham, J. W. M. *et al.* (2021) 'Parallel testing of 241 clinical nasopharyngeal swabs for the detection of SARS-CoV-2
virus on the Cepheid Xpert Xpress SARS-CoV-2 and the Roche cobas SARS-CoV-2 assays', *Clinical Chemistry and*
Laboratory Medicine. De Gruyter Open Ltd, 59(2), pp. E45–E48. doi: 10.1515/CCLM-2020-
1338/MACHINEREADABLECITATION/RIS.

te Velthuis, A. J. W. *et al.* (2009) 'The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent',
Nucleic Acids Research, 38(1), pp. 203–214. doi: 10.1093/nar/gkp904.

Wolters, F. *et al.* (2020) 'Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the
SARS-CoV-2 pandemic', *Journal of Clinical Virology*. Elsevier, 128(May 2020), p. 104426. doi:
10.1016/j.jcv.2020.104426.

World Health Organization (2020) 'Rapid communication on the role of the GeneXpert ® platform for rapid
molecular testing for SARS-CoV-2 in the WHO European Region European Laboratory Initiative on TB, HIV and Viral
Hepatitis: 1 April 2020', (April). Available at: https://apps.who.int/iris/handle/10665/336322 (Accessed: 9
September 2022).

Yau, F. *et al.* (2021) 'Clinical utility of a rapid "on-demand" laboratory-based SARS-CoV-2 diagnostic testing service
in an acute hospital setting admitting COVID-19 patients', *Clinical Infection in Practice*. Elsevier B.V., 12. doi:
10.1016/J.CLINPR.2021.100086.

Zhen, W. *et al.* (2020) 'Clinical Evaluation of Three Sample-To-Answer Platforms for the Detection of SARS-CoV-2',
Journal of Clinical Microbiology. American Society for Microbiology Journals. doi: 10.1128/JCM.00783-20.

The authors have no competing interests to disclose.

All primary research data used to generate this manuscript are included in-text and within Supplementary file 1.

Table 1: Detection of five SARS-CoV-2 Variants. Materials tested were cultured SARS-CoV-2, inactivated by gamma-irradiation. SARS-CoV-2 concentrations were adjusted to target Ct values of 33 and 36, followed by testing with the Xpert SARS-CoV-2/Flu/RSV Combination Test or Xpert SARS-CoV-2/Flu/RSV *PLUS* Combination Test. Each dilution was tested in duplicate (indicated as Replicate 1 [Rep1] and Replicate 2 [Rep2] below).

	SARS-CoV-2 Variant (inactivated culture)	SARS-CoV-2 /Flu/RSV		SARS-CoV-2 /Flu/RSV *PLUS*	
		Rep1	Rep2	Rep1	Rep2
Ct = 33	Wild Type WA-1	30.2	32.2	32.9	32.8
	Alpha B.1.1.7	32.2	32.1	33.4	33.2
	Delta B.1.617.2	33.7	33.8	34.2	34.8
	Omicron BA.1.1	33.7	32.3	33.2	32.7
	Omicron BA.2	33.7	33.4	33.0	32.4
Ct = 36	Wild Type WA-1	35.8	35.5	36.1	36.0
	Alpha B.1.1.7	35.4	35.7	35.6	36.1
	Delta B.1.617.2	36.4	36.4	37.3	37.5
	Omicron BA.1.1	36.4	37.1	35.8	35.9
	Omicron BA.2	36.2	37.6	36.0	35.3

Note: Ct: Cycle threshold

Table 2: Concordance of the Xpert SARS-CoV-2/Flu/RSV Combination Test with the Xpert SARS-CoV-2/Flu/RSV *PLUS* Combination Test for the detection of SARS-CoV-2.

Result with Xpert SARS-CoV-2/Flu/RSV	Result with Xpert SARS-CoV-2/Flu/RSV *PLUS*	
	SARS-CoV-2	
	Positive	Negative
Positive	57	0
Negative	0	103

Table 3: Concordance of the Xpert SARS-CoV-2/Flu/RSV Combination Test with the SARS-CoV-2/Flu/RSV *PLUS* Combination Test for the detection of Influenza A, Influenza B and RSV.

Result with Xpert SARS-CoV-2/Flu/RSV	Result with Xpert SARS-CoV-2/Flu/RSV *PLUS*					
	Influenza A		Influenza B		RSVA/B	
	Positive	Negative	Positive	Negative	Positive	Negative
Positive	21	0	19	1	25	0
Negative	0	139	0	140	0	135

Figure 1: Ct value comparisons between the Xpert SARS-CoV-2/Flu/RSV Combination Test and SARS-CoV-2/Flu/RSV *PLUS* Combination Test. Results shown for: A) SARS-CoV-2; B) Respiratory Syncytial Virus; C) Influenza A; and D) Influenza B. Correlation (R^2) is calculated for each target.